New Triple-Threat attack on aggressive prostate cancer before surgery
NCT ID NCT07027124
Summary
This study is testing a combination of three drugs given before surgery (prostate removal) for men with high-risk prostate cancer. The goal is to see if this treatment can shrink the tumor so much that very little cancer is left after surgery. The study will enroll 40 men whose cancer has specific genetic features that suggest it may respond well to this approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10028, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.